Wolf, C., A. Garding, K. Filarsky, J. Bahlo, S. Robrecht, N. Becker, M. Zucknick, A. Rouhi, A. Weigel, R. Claus, D. Weichenhan, B. Eichhorst, K. Fischer, M. Hallek, F. Kuchenbauer, C. Plass, H. Dohner, S. Stilgenbauer, P. Lichter and D. Mertens (2018). "NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib." Int J Cancer 142(2): 322-333. IF 6,513
Mertens, D. and S. Stilgenbauer (2017). "Ibrutinib-resistant CLL: unwanted
and unwonted!" Blood 129(11):
1407-1409., IF 13.164
C.C. Oakes, M. Seifert, Y. Assenov, L. Gu, M. Przekopowitz, A.S. Ruppert, Q. Wang, C. Imbusch, A. Serva, S. Koser, D. Brocks, D. Lipka, O. Bogatyrova, D. Mertens, M. Zapatka, P. Lichter, H. Döhner, R. Küppers, T. Zenz, S. Stilgenbauer, J.C. Byrd and C. Plass (2015). “Progressive epigenetic programming during B cell maturation is reflected in a continuum of epigenetic disease phenotypes in chronic lymphocytic leukemia.” Nature Genetics, 48(3):253-64, IF 29.352
D.A. Landau*, E. Tausch*, A.N. Taylor-Weiner*, C. Stewart, J. Reiter, J. Bahlo, S. Kluth, I. Bozic, M. Lawrence, S. Bottcher, K. Cibulskis, D. Mertens, C. Sougnez, M. Rosenberg, J.M. Hess, S.L. Carter, J. Edelmann, S. Kless, A. Fink, K. Fischer, S. Gabriel, E. Lander, M. Nowak, H. Dohner, M. Hallek, D. Neuberg**, G. Getz**, S. Stilgenbauer** and C.J. Wu** (2015). „Somatic mutations driving chronic lymphocytic leukemia and their evolution in disease progression and relapse.” Nature, 526(7574):525-30, IF 41.456
Zenz,
T., D. Mertens,
R. Kuppers, H. Dohner and S. Stilgenbauer (2010). From pathogenesis to treatment of chronic
lymphocytic leukaemia. Nat
Rev Cancer 10:1: 37-50, IF 29.538
54. Wolf, C., A. Garding, K. Filarsky, J.
Bahlo, S. Robrecht, N. Becker, M. Zucknick, A. Rouhi, A. Weigel, R. Claus, D.
Weichenhan, B. Eichhorst, K. Fischer, M. Hallek, F. Kuchenbauer, C. Plass, H.
Dohner, S. Stilgenbauer, P. Lichter and D.
Mertens (2018). "NFATC1 activation by DNA
hypomethylation in chronic lymphocytic leukemia correlates with clinical
staging and can be inhibited by ibrutinib." Int J Cancer 142(2): 322-333. IF 6,513
53. Mettang, M., V. Meyer-Pannwitt, G. Karpel-Massler, S.
Zhou, N. O. Carragher, K. J. Fohr, B. Baumann, L. Nonnenmacher, S. Enzenmuller,
M. Dahlhaus, M. D. Siegelin, S. Stroh, D.
Mertens, P. Fischer-Posovszky, E. M. Schneider, M. E. Halatsch, K. M.
Debatin and M. A. Westhoff (2018). "Blocking distinct interactions
between Glioblastoma cells and their tissue microenvironment: A novel
multi-targeted therapeutic approach." Sci
Rep 8(1): 5527. IF 4,259
Zapatka, M., Désiré, L., D. Mertens, Stilgenbauer, S., and
Gierschik, P. (2016). „The Phospholipase C-g2
Mutants R665W and L845F Identified in Ibrutinib-Resistant Chronic Lymphocytic
Leukemia Patients are Hypersensitive to the Rho GTPase Rac2.” J Biol Chem 291(42):
22136-22148., IF 4.258
51.
K. Filarsky, A. Garding, N. Becker, C. Wolf, M. Zucknick, R. Claus, D.
Weichenhan, C. Plass, H. Döhner, S. Stilgenbauer, P. Lichter and D. Mertens (2016). „Krüppel-Like
Factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with
promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling.“
Haematologica, 101(6):e249-53, IF 5.814
50. C.C. Oakes,
M. Seifert, Y. Assenov, L. Gu, M. Przekopowitz, A.S. Ruppert, Q. Wang, C.
Imbusch, A. Serva, S. Koser, D. Brocks, D. Lipka, O. Bogatyrova, D. Mertens, M. Zapatka, P. Lichter, H. Döhner, R. Küppers, T. Zenz,
S. Stilgenbauer, J.C. Byrd and C. Plass (2015). “Progressive epigenetic
programming during B cell maturation is reflected in a continuum of epigenetic
disease phenotypes in chronic lymphocytic leukemia.” Nature Genetics, 48(3):253-64,
IF 29.352
48.
Opel, D., Schnaiter, A., Dodier, D., Jovanovic, M., Gerhardinger, A., Idler,
I., Mertens, D., Bullinger, L.,
Stilgenbauer, S., Fulda, S. (2015). „Targeting inhibitor of apoptosis
proteins by Smac mimetic elicits death in poor prognostic subgroups of chronic
lymphocytic leukemia.“ Int. J. Cancer,
137(12):2959-70, IF 5.007.
47. Baer, C.,
Oakes, CC, Ruppert, AS., Claus, R., Kim-Wanner, SZ., Mertens, D., Zenz, T., Stilgenbauer,
S., Byrd, JC. and Plass, C. (2015). „Epigenetic
silencing of miR-708 enhances NF-kB signaling in chronic lymphocytic leukemia.“
Int J Cancer, 137(6):1352-61, IF 5.007
46. Bhattacharya, N., M. Reichenzeller, M. Caudron-Herger, S. Haebe, N. Brady, S. Diener, M. Nothing, H. Dohner, S. Stilgenbauer, K. Rippe and D. Mertens (2015). "Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6." Int J Cancer, 136(1):65-73, IF 6.198
45. Stilgenbauer, S., A. Schnaiter, P. Paschka, T. Zenz, M. Rossi, K. Dohner, A. Buhler, S. Bottcher, M. Ritgen, M. Kneba, D. Winkler, E. Tausch, P. Hoth, J. Edelmann, D. Mertens, L. Bullinger, M. Bergmann, S. Kless, S. Mack, U. Jager, N. Patten, L. Wu, M. K. Wenger, G. Fingerle-Rowson, P. Lichter, M. Cazzola, C. M. Wendtner, A. M. Fink, K. Fischer, R. Busch, M. Hallek and H. Dohner (2014). "Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial." Blood, in press. IF 9.060
44. Skorka, K., N. Bhattacharya, P. Wlasiuk, M. Kowal, D. Mertens, A. Dmoszynska and K. Giannopoulos (2014). "Thalidomide regulation of NF-kappaB proteins limits Tregs activity in chronic lymphocytic leukemia." Adv Clin Exp Med 23(1): 25-32., IF 0.293
43. C. Oakes, R. Claus, L. Gu, Y. Assenov, J. Hüllein, M. Zucknick, D. Brocks, O. Bogatyrova, C. Schmidt, L. Rassenti, TJ. Kipps, Mertens, D., P. Lichter, H. Dohner, S. Stilgenbauer, JC. Byrd, T. Zenz and C. Plass (2013) Heterogeneity and evolution of DNA methylation are linked to genetic aberrations in chronic lymphocytic leukemia, Cancer Disvovery, 4(3):348-361, IF 10.143
42. Allegra, D., Bilan, V., Garding, A., Döhner, H., Stilgenbauer, S., Kuchenbauer, F., Mertens, D. (2013), Defective DROSHA processing contributes to downregulation of miR-15/-16 in chronic lymphocytic leukemia, Leukemia, 28(1):98-107, IF 10.164
41. Schnaiter, A., Pascka, P., Rossi, M., Zenz, T., Bühler, A., Winkler, D., Cazzola, M., Döhner, K., Edelmann, J., Mertens, D., Kless, S., Mack, S., Busch, E., Hallek, M., Döhner, H., Stilgenbauer, S. (2013), NOTCH1, SF3B1 and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG, Blood,122(7):1266-1270, IF 9.060
40. Wei, QX., Claus, R., Hielscher, T., Mertens, D., Raval, A., Oakes, CC., Tanner, ST., de la Chapelle, A., Byrd, JC., Stilgenbauer, S., Plass, C. (2013), Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia, PLOS ONE, 8(1) e55261, IF 4.091
39. Garding, A., Bhattacharya, N., Claus, R., Ruppel, M., Tschuch, C., Filarsky, K., Idler, I., Zucknick, M., Caudron-Herger, M., Oakes, C., Fleig, V., Keklikoglou, I., Allegra, D., Serra, L., Thakurela, S., Tiwari, V., Weichenhan, D., Benner, A., Radlwimmer, B., Zentgraf, H., Wiemann, S., Rippe, K., Plass, C., Döhner, H., Lichter, P. Stilgenbauer, S., Mertens, D. (2013), Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the in cis downregulation of a gene cluster that targets NF-kB, PLOS Genetics, 9(4): e1003373, IF 8.694
38.
Jebaraj,
BMC., Kienle, D., Lechel, A.,
Mertens, D., Heuberger, M., Ott,
D., Rosenwald, A., Barth, T., Möller, P., Zenz, T.,
Döhner, H., Stilgenbauer, S.. (2013), "Telomere
Length in Mantle Cell Lymphoma", Blood, 121(7):1184-7, IF
8.989
34. Garding, A., Bhattacharya, N., Haebe, S., Mueller, F., Weichenhan, D., Idler, I., Ickstadt, K., Stilgenbauer, S. & Mertens, D. (2013) "TCL1A and ATM are coexpressed in chronic lymphocytic leukemia cells without deletion of 11q." Haematologica, 98(2):269-73. IF 6.416
37. Faber,
K., Bullinger, L., Ragu, C., Garding,
A., Mertens, D., Miller, C., Martin, D.,
Walcher,
D., Döhner, K., Döhner, H., Claus, R., Plass, C.,
Sykes, S.M., Lane, S.W.,
Scholl, C., & Fröhling, S. (2012), “Myeloid
leukemogenesis by CDX2 involves
repression of KLF4 and deregulated PPAR signalling”, JCI, 123(1):
299-314, IF
13.069
36.
Edelmann, J., Holzmann, K., Miller, F., Winkler, D., Bühler,
A.,
Zenz, T., Bullinger, L., Kühn, M.W.M., Gerhardinger, A.,
Blöhdorn, J., Radtke,
I., Su, X., Ma, J., Pounds, S., Hallek, M., Lichter, P., Korbel, J.,
Busch, R., Mertens, D., Downing, J.R.,
Stilgenbauer, S., &
Döhner H. (2012), “High-Resolution Genomic Profiling
of Chronic Lymphocytic
Leukemia Reveals New Recurrent Genomic Alterations”, Blood, 120(24):4783-94,
IF
8.989
35.
Claus, R., Lucas, D. M., Stilgenbauer, S., Ruppert,
A. S., Yu, L., Zucknick, M., Mertens, D.,
Buhler, A., Oakes, C. C., Larson, R. A., Kay, N. E., Jelinek, D. F.,
Kipps, T.
J., Rassenti, L. Z., Gribben, J. G., Dohner, H., Heerema, N. A.,
Marcucci, G.,
Plass, C. & Byrd, J. C. (2012) "Quantitative DNA Methylation
Analysis
Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression
and
Predictive of Prognosis in Chronic Lymphocytic Leukemia." J Clin Oncol, 30(20):2483-91.
IF 18.970
33. Grasedieck,
S., Scholer, N., Bommer, M., Niess, J. H., Tumani, H., Rouhi, A.,
Bloehdorn,
J., Liebisch, P., Mertens, D.,
Dohner, H., Buske, C., Langer, C. & Kuchenbauer, F. (2012)
"Impact of
serum storage conditions on microRNA stability." Leukemia, 26(11):2414-6.
IF 8.966
32. Grzywnowicz,
M., Zaleska, J., Mertens, D.,
Tomczak, W., Wlasiuk, P., Kosior, K., Piechnik, A., Bojarska-Junak, A.,
Dmoszynska, A. & Giannopoulos, K. (2012) "Programmed death-1
and its
ligand are novel immunotolerant molecules expressed on leukemic B cells
in
chronic lymphocytic leukemia." PloS
one, 7, e35178.
IF
4.411
31. Allegra,
D. & Mertens, D.
(2011) "In-vivo quantification of primary microRNA
processing by Drosha with a luciferase based system." Biochemical
and biophysical research communications, 406,
501-505.
IF
2.595
30. Bhattacharya,
N., Diener, S., Idler, I. S.,
Rauen, J., Habe, S., Busch, H., Habermann, A., Zenz, T.,
Dohner, H.,
Stilgenbauer, S. & Mertens, D.
(2011) "Nurse-like cells show deregulated expression of genes involved
in
immunocompetence." Br J Haematol,
154, 349-356.
IF
4.597
29. Mohr,
J., Helfrich, H., Fuge, M., Eldering, E., Buhler, A., Winkler, D.,
Volden, M.,
Kater, A. P., Mertens, D., Te Raa,
D.,
Dohner, H., Stilgenbauer, S. & Zenz, T. (2011) "DNA
damage-induced
transcriptional program in CLL: biological and diagnostic implications
for
functional p53 testing." Blood,
117, 1622-1632.
IF
10.555
28. Wittig-Blaich,
S. M., Kacprzyk, L. A., Eismann, T., Bewerunge-Hudler, M., Kruse, P.,
Winkler,
E., Strauss, W. S., Hibst, R., Steiner, R., Schrader, M., Mertens, D., Sultmann, H. &
Wittig, R. (2011)
"Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3
prostate
cancer cells." Neoplasia,
13, 579-589. IF 5.476
27. Bhattacharya,
N., Diener, S., Idler, I. S.,
Barth, T. F., Rauen, J., Habermann,
A., Zenz, T., Moller, P., Dohner, H., Stilgenbauer, S. & Mertens, D. (2011) "Non-malignant
B cells and chronic lymphocytic leukemia cells induce a pro-survival
phenotype
in CD14+ cells from peripheral blood." Leukemia,
25, 722-726. IF 8.296
26. Bhattacharya,
N., Sarno, A., Idler, I. S., Fuhrer, M., Zenz, T., Dohner,
H., Stilgenbauer,
S. & Mertens, D. (2010)
"High-throughput detection of nuclear factor-kappaB activity using a
sensitive oligo-based chemiluminescent enzyme-linked immunosorbent
assay."
Int J Cancer,
127, 404-411.
IF 4.722
25. Philippen,
A., Diener, S., Zenz, T.,
Dohner, H., Stilgenbauer, S. & Mertens,
D. (2010) "SYK carries no activating point mutations in
patients with
chronic lymphocytic leukaemia (CLL)." Br
J Haematol, 150, 633-636.
IF 4.597
24. Winkler,
D., Schneider, C., Zucknick, M., Bogelein, D., Schulze, K., Zenz, T.,
Mohr, J.,
Philippen, A., Huber, H., Buhler,
A., Habermann, A., Benner, A., Dohner, H., Stilgenbauer, S. & Mertens, D. (2010) "Protein
expression analysis of chronic lymphocytic leukemia defines the effect
of
genetic aberrations and uncovers a correlation of CDK4, P27 and P53
with
hierarchical risk." Haematologica,
95, 1880-1888.
IF
6.416
23. Zenz,
T., Mohr, J., Edelmann, J., Sarno, A.,
Hoth, P., Heuberger, M., Helfrich, H., Mertens,
D., Dohner, H. & Stilgenbauer, S. (2009) "Treatment
resistance in
chronic lymphocytic leukemia: the role of the p53 pathway." Leuk Lymphoma, 50,
510-513. IF 2.397
22. Zenz,
T., Mohr, J., Eldering,
E., Kater, A. P., Buhler, A., Kienle, D., Winkler, D., Durig, J., van
Oers, M.
H., Mertens, D., Dohner, H.
&
Stilgenbauer, S. (2009) "miR-34a as part of the resistance network in
chronic lymphocytic leukemia." Blood,
113, 3801-3808.
IF
10.555
21. Giannopoulos,
K., Mertens, D., Buhler, A., Barth,
T. F., Idler, I., Moller, P.,
Krober, A., Greiner, J., Chocholska, S., Dmoszynska, A., Rolinski, J.,
Dohner,
H., Stilgenbauer, S. & Schmitt, M. (2009) "The candidate
immunotherapeutical target, the receptor for hyaluronic acid-mediated
motility,
is associated with proliferation and shows prognostic value in B-cell
chronic
lymphocytic leukemia." Leukemia,
23, 519-527.
IF
8.296
20. Loeder,
S., Zenz, T., Schnaiter, A., Mertens, D.,
Winkler, D., Dohner, H., Debatin, K. M., Stilgenbauer, S. &
Fulda, S.
(2009) "A novel paradigm to trigger apoptosis in chronic lymphocytic
leukemia." Cancer Res,
69, 8977-8986.
IF
7.543
19. Idler,
I., Giannopoulos, K., Zenz, T., Bhattacharya,
N., Nothing, M., Dohner,
H., Stilgenbauer, S. & Mertens, D.
(2009) "Lenalidomide treatment of chronic lymphocytic leukaemia
patients
reduces regulatory T cells and induces Th17 T helper cells." Br J Haematol, 148,
948-950.
IF 4.597
18. Zenz,
T., Habe, S., Denzel, T., Mohr, J.,
Winkler, D., Buhler, A., Sarno, A.,
Groner, S., Mertens, D., Busch, R.,
Hallek, M., Dohner, H. & Stilgenbauer, S. (2009) "Detailed
analysis of
p53 pathway defects in fludarabine-refractory chronic lymphocytic
leukemia
(CLL): dissecting the contribution of 17p deletion, TP53 mutation,
p53-p21
dysfunction, and miR34a in a prospective clinical trial." Blood, 114, 2589-2597.
IF 10.555
17. Tschuch,
C., Schulz, A., Pscherer, A.,
Werft, W., Benner, A., Hotz-Wagenblatt, A., Barrionuevo,
L. S., Lichter, P. & Mertens,
D. (2008) "Off-target effects of siRNA specific for
GFP." BMC Mol Biol,
9,
60.
IF
2.848
16. Kalla,
C., Scheuermann, M. O., Kube, I., Schlotter, M., Mertens,
D., Dohner, H., Stilgenbauer, S. & Lichter, P. (2007)
"Analysis of 11q22-q23 deletion target genes in B-cell chronic
lymphocytic
leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B." Eur J Cancer, 43,
1328-1335.
IF 4.121
15. Prowatke,
I., Devens, F., Benner, A., Grone, E. F., Mertens,
D., Grone, H. J., Lichter, P. & Joos, S. (2007)
"Expression
analysis of imbalanced genes in prostate carcinoma using tissue
microarrays." Br J Cancer,
96, 82-88.
IF
4.346
14. Henrich,
K. O., Fischer, M., Mertens, D.,
Benner, A., Wiedemeyer, R., Brors, B., Oberthuer, A., Berthold, F.,
Wei, J. S.,
Khan, J., Schwab, M. & Westermann, F. (2006) "Reduced
expression of
CAMTA1 correlates with adverse outcome in neuroblastoma patients." Clin Cancer Res, 12,
131-138.
IF 6.747
13. Kienle,
D., Benner, A., Krober, A., Winkler, D., Mertens,
D., Buhler, A., Seiler, T., Jager, U., Lichter, P., Dohner,
H. &
Stilgenbauer, S. (2006) "Distinct gene expression patterns in chronic
lymphocytic leukemia defined by usage of specific VH genes." Blood, 107, 2090-2093.
IF 10.555
12. Adamowicz,
M., Radlwimmer, B., Rieker, R. J., Mertens,
D., Schwarzbach, M., Schraml, P., Benner, A., Lichter, P.,
Mechtersheimer,
G. & Joos, S. (2006) "Frequent amplifications and abundant
expression
of TRIO, NKD2, and IRX2 in soft tissue sarcomas." Genes
Chromosomes Cancer, 45, 829-838.
IF 3.858
11. Wolf,
S., Mertens, D., Pscherer, A.,
Schroeter, P.,
Winkler, D., Grone, H. J., Hofele, C., Hemminki, K.,
Kumar, R.,
Steineck, G., Dohner, H., Stilgenbauer, S. & Lichter, P. (2006)
"Ala228 variant of trail receptor 1 affecting the ligand binding site
is
associated with chronic lymphocytic leukemia, mantle cell lymphoma,
prostate
cancer, head and neck squamous cell carcinoma and bladder cancer." Int J Cancer, 118,
1831-1835.
IF 4.722
10. Mannherz,
O., Mertens, D., Hahn, M. &
Lichter, P. (2006) "Functional screening for proapoptotic genes by
reverse
transfection cell array technology." Genomics,
87, 665-672.
IF
3.327
9. Mertens,
D., Wolf, S., Tschuch,
C., Mund, C., Kienle, D., Ohl, S.,
Schroeter, P., Lyko, F.,
Dohner, H., Stilgenbauer, S. & Lichter, P. (2006) "Allelic
silencing
at the tumor-suppressor locus 13q14.3 suggests an epigenetic
tumor-suppressor
mechanism." Proc Natl Acad Sci U
S A, 103, 7741-7746.
IF 9.432
8. Kienle,
D. L., Korz, C., Hosch, B., Benner, A., Mertens,
D., Habermann, A., Krober, A., Jager, U., Lichter, P.,
Dohner, H. &
Stilgenbauer, S. (2005) "Evidence for distinct pathomechanisms in
genetic
subgroups of chronic lymphocytic leukemia revealed by quantitative
expression
analysis of cell cycle, activation, and apoptosis-associated genes." J Clin Oncol, 23,
3780-3792.
IF 17.793
7. Kalla,
C., Nentwich, H., Schlotter, M., Mertens,
D., Wildenberger, K., Dohner, H., Stilgenbauer, S. &
Lichter, P. (2005)
"Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia
disrupts two novel genes." Genes
Chromosomes Cancer, 42, 128-143.
IF 3.858
6. Mertens,
D., Wolf, S., Schroeter,
P., Schaffner, C., Dohner,
H., Stilgenbauer, S. & Lichter, P. (2002) "Down-regulation of
candidate tumor suppressor genes within chromosome band 13q14.3 is
independent
of the DNA methylation pattern in B-cell chronic lymphocytic leukemia."
Blood, 99,
4116-4121.
IF 10.555
5. Korz,
C., Pscherer, A., Benner, A., Mertens,
D., Schaffner, C., Leupolt, E., Dohner, H., Stilgenbauer, S.
& Lichter,
P. (2002) "Evidence for distinct pathomechanisms in B-cell chronic
lymphocytic leukemia and mantle cell lymphoma by quantitative
expression
analysis of cell cycle and apoptosis-associated genes." Blood,
99, 4554-4561.
IF 10.555
4. Wolf,
S., Mertens, D., Schaffner, C.,
Korz, C., Dohner, H., Stilgenbauer, S. & Lichter, P. (2001)
"B-cell
neoplasia associated gene with multiple splicing (BCMS): the candidate
B-CLL
gene on 13q14 comprises more than 560 kb covering all critical
regions." Hum Mol Genet,
10, 1275-1285.
IF 7.386
3. Mertens, D., Wolf, S., Bullinger, L., Ohl, S., Schaffner, C., Dohner, H.,
Stilgenbauer, S. & Lichter, P. (2000) "BCMSUN, a candidate gene
for
B-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an
independently expressed homolog on 1p22- p31, BCMSUN-like." Int J Cancer, 88,
692-697.
IF 4.722
2. Bullinger,
L., Leupolt, E., Schaffner, C., Mertens,
D., Bentz, M., Lichter, P., Dohner, H. &
Stilgenbauer, S. (2000)
"BCL10 is not the gene inactivated by mutation in the 1p22 deletion
region
in mantle cell lymphoma." Leukemia,
14, 1490-1492.
IF
8.296
1. Lammer,
C., Wagerer, S., Saffrich, R., Mertens,
D., Ansorge, W. & Hoffmann, I. (1998) "The cdc25B
phosphatase is
essential for the G2/M phase transition in human cells." J
Cell Sci, 111 ( Pt 16),
2445-2453.
IF
6.144
Reviews
19. Mertens, D.
and S. Stilgenbauer (2017). "Ibrutinib-resistant
CLL: unwanted and unwonted!" Blood 129(11): 1407-1409., IF 13.164
18.
Meyer-Pannwitt, V., Steinbrecher, D., Stilgenbauer, S., Mertens, D. (2016). "Rapid detection of ATM/p53
function with p27Kip FACS analysis: a novel diagnostic tool for CLL?" Leukemia & Lymphoma, 58(1): 6-7., IF 3.093
17.
E. Tausch, D. Mertens, S. Stilgenbauer
(2016). „Genomic Features: Impact on Pahtogenesis and
Treatment of Chronic Lymphocytic Leukemia.” Oncol
Res Treat, 39(1-2):34-40. IF 1.333
16. Mertens, D. and S. Stilgenbauer (2014). "Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?" J Clin Oncol, 32(9): 869-872, IF 18.038
15. Tausch, E., Mertens, D. and Stilgenbauer, S. (2014). "Advances in treating chronic lymphocytic leukemia." F1000Prime Reports, 6(65), no IF
14. Grasedieck, S., Sorrentino, A., Langer, C., Buske, C., Döhner, H., Mertens, D., Kuchenbauer, F. (2013) "Circulating microRNAs in Hematological Diseases: Principles, Challenges and Perspectives." Blood, 121(25):4977-4984, IF 9.989
13. Kugler,
S., Schnaiter, A., Stilgenbauer, S.
& Mertens,
D. (2013) "Missing
the Notch in NOTCH1" Leukemia &
Lymphoma, 54(8):1579-1580.
IF 2.580
12. Mertens, D.
& Stilgenbauer, S. (2012) "CLL and deletion 13q14: merely the
miRs?" Blood,
119,
2974-2975. IF 10.558
11.
Idler, I.,
Bhattacharya, N., Dohner, H., Stilgenbauer, S. & Mertens,
D. (2011) "Immune modulatory agents in hematopoietic
malignancies." Cancer treatment
reviews, 37 Suppl 1, S2-7. IF
6.811
10. Schnaiter,
A., Mertens, D. &
Stilgenbauer,
S. (2011) "Genetics of chronic lymphocytic leukemia." Clinics
in laboratory medicine,
31, 649-658, ix. IF 1.966
9. Stilgenbauer,
S. & Mertens, D. (2011)
"Toward chemotherapy-free treatment of CLL." Blood,
118, 3451-3452. IF
10.558
8.
Mertens, D.,
Bullinger, L. &
Stilgenbauer, S. (2011) "Chronic lymphocytic leukemia--genomics lead
the
way." Haematologica,
96,
1402-1405. IF 6.532
7. Giannopoulos,
K., Mertens,
D., Stilgenbauer, S. (2011), Treating chronic lymphocytic
leukemia with
Thalidomide and Lenalidomide, Current Opinion in
Pharmacotherapy, 12(18):2857-64,
IF 2.403
6. Zenz,
T., Mertens, D., Dohner, H.
&
Stilgenbauer, S. (2011) "Importance of genetics in chronic lymphocytic
leukemia." Blood reviews,
25, 131-137. IF 10.558
5. Zenz,
T., Mertens, D. &
Stilgenbauer, S.
(2010) "Biological diversity and risk-adapted treatment of chronic
lymphocytic leukemia." Haematologica,
95, 1441-1443. IF 6.416
4. Zenz,
T.,
Frohling, S., Mertens, D., Dohner,
H. & Stilgenbauer, S. (2010) "Moving from prognostic to
predictive
factors in chronic lymphocytic leukaemia (CLL)." Best
Pract Res Clin Haematol, 23, 71-84. IF
3.134
3. Zenz,
T., Mertens, D., Kuppers, R.,
Dohner, H.
& Stilgenbauer, S. (2010) "From pathogenesis to treatment of
chronic
lymphocytic leukaemia." Nat Rev
Cancer, 10, 37-50. IF
29.538
2. Mertens, D., Philippen,
A., Ruppel, M., Allegra, D., Bhattacharya, N., Tschuch, C.,
Wolf, S., Idler, I., Zenz, T.
&
Stilgenbauer, S. (2009) "Chronic lymphocytic leukemia and 13q14: miRs
and
more." Leuk Lymphoma, 50, 502-505. IF 2.397
1. Zenz, T., Mertens, D., Dohner, H. & Stilgenbauer, S. (2008) "Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications." Leuk Lymphoma, 49, 864-873. IF 2.397
Book Chapters
2. Bilan, V., Allegra, D., Kuchenbauer, F., Mertens, D. (2014) "In vivo processing assay based on a dual-luciferase reporter system to evaluate DROSHA enzymatic activity." in miRNA Maturation, Arenz, C., ed. (Humana Press), 87-93, 2014
1. Bloehdorn, J., Rouhi, A., Dhanyamraju, P., Krowiorz, K., Schneider, E., Langer,C., Mertens, D., Stilgenbauer, S., Kuchenbauer, F. (2013) "MicroRNAs in hematologic malignancies." in Non-coding RNAs and Cancer, Fabbri, M., ed. (Springer Science & Business Media), chapter 5.2